Insight into the nature of the CRP-coronary event association using Mendelian randomization

Department of Pharmacological Sciences, University of Milan, Milano, Lombardy, Italy
International Journal of Epidemiology (Impact Factor: 9.2). 08/2006; 35(4):922-31. DOI: 10.1093/ije/dyl041
Source: PubMed

ABSTRACT It is unclear wheather the association between C-reactive protein (CRP) and incident coronary events is free from bias and confounding. Individuals homozygous for a +1444C>T polymorphism in the CRP gene have higher circulating concentrations of CRP. Since the distribution of this polymorphism occurs at random during gamete formation, its association with coronary events should not be biased or confounded.
We calculated the weighted mean difference in CRP between individuals with variants of the +1444C>T polymorphism in the CRP gene among 4,659 European men from six studies (genotype-intermediate phenotype studies). We used this difference together with data from previous observational studies to compute an expected odds ratio (OR) for non-fatal myocardial infarction (MI) among individuals homozygous for the T allele. We then performed four new genetic association studies (6,201 European men) to obtain a summary OR for the association between the +1444C>T polymorphism and non-fatal MI (genotype-disease studies).
CRP was 0.68 mg/l [95% confidence interval (95% CI) 0.31-1.10; P = 0.0001] higher among subjects homozygous for the +1444-T allele, with no confounding by a range of covariates. The expected ORs among TT subjects for non-fatal MI corresponding to this difference in CRP was 1.20 (95% CI 1.07-1.38) using the Reykjavik Heart study data and 1.25 (1.09-1.43) for all observational studies to 2004. The estimate for the observed adjusted-OR for non-fatal MI among TT subjects was 1.01 (95% CI 0.74-1.38), lower than both expected ORs.
A common CRP gene polymorphism is associated with important differences in CRP concentrations, free from confounding. The null association of this variant with coronary events suggests possible residual confounding (or reverse causation) in the CRP-coronary event association in observational studies, though the confidence limits are still compatible with a modest causal effect. Additional studies of genotype (or haplotype) and coronary events would help clarify whether or not the link between CRP and coronary events in observational studies is causal.

  • [Show abstract] [Hide abstract]
    ABSTRACT: C-reactive protein (CRP) concentration is a heritable systemic marker of inflammation that is associated with cardiovascular disease risk. Genome Wide Association Studies have identified CRP-associated common variants associated in approximately 25 genes. Our aims were to apply exome sequencing to 1) assess whether the candidate loci contain rare coding variants associated with CRP levels and; 2) perform an exome-wide search for rare variants in novel genes associated with CRP levels. We exome sequenced 6,050 European Americans and 3,109 African Americans from the NHLBI-ESP and the CHARGE consortia and performed association tests of sequence data with measured CRP levels. In single variant tests across candidate loci, a novel rare (MAF=0.16%) CRP coding variant (rs77832441-A; p.Thr59Met) was associated with 53% lower mean CRP levels (P=2.9x10(-6)). We replicated the association of rs77832441 in an exome array analysis of 11,414 European Americans (P=3.0x10(-15)). Despite a strong effect on CRP levels, rs77832441 was not associated with inflammation-related phenotypes including Coronary Heart Disease. We also found evidence for an African American-specific association of APOE-ϵ2 rs7214 with higher CRP levels. At the exome-wide significance level (P<5.0x10(-8)), we confirmed associations for reported common variants of HNF1A, CRP, IL6R, and TOMM40-APOE. In gene-based tests, a burden of rare/low frequency variation in CRP in European Americans (P≤6.8 x10(-4)) and RORA in African Americans (P=1.7 x10(-3)) were associated with CRP levels at the candidate gene-level (P<2.0 x10(-3)). This inquiry did not elucidate novel genes, but instead demonstrated that variants distributed across the allele-frequency spectrum within candidate genes contribute to CRP levels.
    Human Molecular Genetics 09/2014; DOI:10.1093/hmg/ddu450 · 6.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiological research over the last 50 years has discovered a plethora of biomarkers (including molecules, traits or other diseases) that associate with coronary artery disease (CAD) risk. Even the strongest association detected in such observational research precludes drawing conclusions about the causality underlying the relationship between biomarker and disease. Mendelian randomization (MR) studies can shed light on the causality of associations, i.e whether, on the one hand, the biomarker contributes to the development of disease or, on the other hand, the observed association is confounded by unrecognized exogenous factors or due to reverse causation, i.e. due to the fact that prevalent disease affects the level of the biomarker. However, conclusions from a MR study are based on a number of important assumptions. A prerequisite for such studies is that the genetic variant employed affects significantly the biomarker under investigation but has no effect on other phenotypes that might confound the association between the biomarker and disease. If this biomarker is a true causal risk factor for CAD, genotypes of the variant should associate with CAD risk in the direction predicted by the association of the biomarker with CAD. Given a random distribution of exogenous factors in individuals carrying respective genotypes, groups represented by the genotypes are highly similar except for the biomarker of interest. Thus, the genetic variant converts into an unconfounded surrogate of the respective biomarker. This scenario is nicely exemplified for LDL cholesterol. Almost every genotype found to increase LDL cholesterol level by a sufficient amount has also been found to increase CAD risk. Pending a number of conditions that needed to be fulfilled by the genetic variant under investigation (e.g. no pleiotropic effects) and the experimental set-up of the study, LDL cholesterol can be assumed to act as the functional component that links genotypes and CAD risk and, more importantly, it can be assumed that any modulation of LDL cholesterol-by whatever mechanism-would have similar effects on disease risk. Therefore, MR analysis has tremendous potential for identifying therapeutic targets that are likely to be causal for CAD. This review article discusses the opportunities and challenges of MR studies for CAD, highlighting several examples that involved multiple biomarkers, including various lipid and inflammation traits as well as hypertension, diabetes mellitus, and obesity.
    European Heart Journal 06/2014; 35(29). DOI:10.1093/eurheartj/ehu208 · 14.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: According to several epidemiological and clinical studies, the concentration of C-reactive protein (CRP) in blood is associated with the risk of coronary heart disease (CHD). However, these studies are limited in high incidence and prevalence area of North-West India. The present case control study investigated the contribution of three relevant CRP single nucleotide polymorphisms: -717A>G located in the promoter region (rs2794521), +1059G>C on exon2 (rs1800947) and +1444C>T in the 3' UTR (rs1130864) in 180 angiographically verified CHD cases and 175 control subjects. Minor allele frequencies (G, C and T) of rs2794521, rs1800947 and rs1130864 are observed to be 21.1, 11.7, 29.4 and 11.4, 10.0, 19.7 % in CHD cases and controls respectively. AA genotype of -717A>G and TT genotype of +1444C>T were significantly associated (P = 0.02 & 0.03 respectively) with the risk of CHD whereas, +1059G and +1444T were found to be strongly related (P = 0.023 & P = 0.008 respectively) with multivariable adjusted CRP levels. AGT Haplotype was significantly associated with the adjusted CRP levels (P < 0.05). Disease association analysis revealed that haplotype AGT influences CHD risk (OR 2.4, 95 % CI 1.23-4.84, P = 0.006) which exacerbates after correcting the confounding effects of risk variables (OR 2.5, 95 % CI 1.27-4.99, P = 0.004). With the global index of Akaike information criterion, it has been observed that the carrying each single unit of this susceptibility haplotype increases CHD risk by a value of 2.41 ± 0.439 (β ± SE) in the recessive mode.
    Molecular Biology Reports 06/2014; 41(9). DOI:10.1007/s11033-014-3459-0 · 1.96 Impact Factor

Full-text (2 Sources)

Available from
May 19, 2014